A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

This phase 2 study assesses the efficacy and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (anti-angiogenic agent) in women with pretreated recurrent or metastatic cervical cancer (ClinicalTrials.gov NCT03827837). Patients with histologically or cytologically confirmed cervical squam...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Lingfang, Zhou, Qi, Gao, Yunong, Hu, Wenjing, Lou, Ge, Sun, Hong, Zhu, Jianqing, Shu, Jin, Zhou, Xianfeng, Sun, Rong, Wu, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732039/
https://www.ncbi.nlm.nih.gov/pubmed/36481736
http://dx.doi.org/10.1038/s41467-022-35133-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732039/
https://www.ncbi.nlm.nih.gov/pubmed/36481736
http://dx.doi.org/10.1038/s41467-022-35133-4

Ejemplares similares